# Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

> **NCT02589977** · PHASE4 · COMPLETED · sponsor: **Marvin W. Kronenberg, M.D.** · enrollment: 55 (actual)

## Conditions studied

- Heart Failure, Diastolic
- Diastolic Heart Failure
- Hypertension

## Interventions

- **DRUG:** regadenoson

## Key facts

- **NCT ID:** NCT02589977
- **Lead sponsor:** Marvin W. Kronenberg, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-01-21
- **Final completion:** 2020-01-21
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589977, "Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02589977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*